What is Tesamorelin?

Tesamorelin is a synthetic analogue of human growth-hormone-releasing hormone (GHRH 1-44), engineered with structural modifications that increase its stability compared with the native peptide. That stability is what makes it a dependable tool for studying hypothalamic–pituitary communication and growth-hormone regulatory pathways under controlled laboratory conditions.

Research use only. Tesamorelin is supplied strictly for in-vitro laboratory research. This page does not describe dosing, administration, or use in humans or animals, and makes no therapeutic claims.

What researchers study

In biochemical and cellular systems, Tesamorelin binds to and activates the GHRH receptor on pituitary-derived cells, initiating intracellular cascades that regulate growth-hormone synthesis and secretion. Experimental work commonly characterises receptor-binding behaviour, cAMP-dependent signalling, and downstream transcriptional responses under defined exposure conditions. As always, observed effects vary with concentration, exposure duration and model system, so it is used to characterise GHRH-receptor signalling rather than to infer physiological outcomes.

Typical research applications include:

• Analysing GHRH-receptor activation and associated signalling pathways
• Studying growth-hormone regulatory mechanisms in pituitary-based models
• In-vitro work on peptide stability, receptor selectivity and signalling specificity

How it is supplied

Tesamorelin is supplied as a lyophilised vial with a batch-specific Certificate of Analysis (HPLC + mass spectrometry), stored refrigerated at 2–8°C.

Related reading

• Compare with another GHRH analogue: what is CJC-1295?
• New to the topic? What are research peptides?